Also trades as: ARTLW (NASDAQ) · $vol 0M
ARTL NASDAQ
Artelo Biosciences, Inc.
1W: -18.9%
1M: -43.6%
3M: -62.5%
YTD: -67.8%
1Y: -91.4%
3Y: -95.5%
5Y: -99.4%
$3.68
-0.15 (-3.92%)
Weekly Expected Move ±46.2%
$0
$2
$4
$5
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-04-09
Earliest Filing
2026-02-05
Latest Filing
partner: 5
investor: 2
Counterparties (Filed by ARTL)
7 relationshipsCompanies named in ARTL's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Square Gate Capital Master Fund, LLC – Series 5 | — | investor | Investor entering into an Equity Purchase Agreement to purchase up to $50 million in common stock. | 2026-02-05 | View |
| R. F. Lafferty & Co., Inc. | — | partner | Sole book-running manager and underwriter for the common stock offering. | 2025-09-05 | View |
| ABK Labs, Inc. | — | partner | Consulting agreement for strategic advisory services and issuance of warrants | 2025-08-07 | View |
| R.F. Lafferty & Co., Inc. | — | partner | Entered into an At-The-Market Offering Agreement to act as sales agent for the Company's equity program. | 2025-07-18 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Institutional investor entering a purchase agreement to buy up to $20.0 million worth of the Company's common stock over | 2022-05-16 | View |
| Ladenburg Thalmann & Co. Inc. | — | partner | Entered into an At Market Issuance Sales Agreement to sell the Company's common stock. | 2021-04-09 | View |
| Maxim Group, LLC | MMS | partner | Previous counterparty to an Equity Distribution Agreement that was terminated. | 2021-04-09 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-27 | Bylaws Amendment; Regulation FD; Exhibits | View | |
| 2026-07-17 | Shareholder Vote | View | |
| 2026-05-27 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-04-07 | Other Events; Exhibits | View | |
| 2026-03-30 | Material Agreement; Unregistered Equity Sales; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-03-26 | Material Agreement; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-03-17 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2026-03-06 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2026-02-05 | Other Events | View | |
| 2026-02-05 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2026-01-30 | Submission of Matters to a Vote of Security Holders | View | |
| 2026-01-16 | Notice of Delisting or Transfer | View | |
| 2026-01-02 | Regulation FD Disclosure | View | |
| 2025-11-25 | Notice of Delisting or Transfer | View | |
| 2025-11-14 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-10-31 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-10-27 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-10-17 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-10-01 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-09-15 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR